Human Growth Hormone - CAM 339

Description
Recombinant human growth hormone (GH) is approved by the U.S. Food and Drug Administration (FDA) for various indications and is also proposed for various off-label indications, such as cystic fibrosis and treatment of older adults without documented growth hormone deficiency (GHD).

For individuals who have proven GHD who receive human GH, the evidence includes randomized controlled trials (RCTs), large observational studies, and meta-analyses. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Studies have found that, for patients with documented GHD and clinical manifestations such as short stature, GH replacement has been shown to improve growth velocity and final height achieved. In addition, studies have shown that GH therapy can ameliorate the secondary manifestations of GHD such as increase in lean muscle mass and bone mineral density seen primarily in older children and adults. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to Prader-Willi syndrome who receive human GH, the evidence includes RCTs and a cohort study. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Several RCTs have found improvements in height, body mass index, head circumference, and motor development in children with Prader-Willi syndrome treated with GH. One RCT reported that GH treatment continued to benefit individuals with Prader-Willi syndrome who had attained adult height, by significantly lowering fat mass and increasing lean body mass. GH treatment was not found to significantly affect problem behavior or total IQ. Studies have found increased risk of adverse events in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment and thus GH is contraindicated. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to chronic renal insufficiency who receive human GH, the evidence includes RCTs and systematic reviews. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Systematic reviews of RCTs have found significantly increased height and height velocity in children with short stature associated with chronic renal insufficiency who are treated with GH therapy compared with other interventions. There were no significant increases in adverse events related to renal function. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to Turner syndrome who receive human GH, the evidence includes RCTs and observational studies. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. RCTs and observational studies have found that GH therapy increases height outcomes (e.g., final height, height velocity) and positively affects craniofacial development in children with short stature and craniofacial complex due to Turner syndrome compared with placebo or no treatment. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to Noonan syndrome who receive human GH, the evidence includes a systematic review of a controlled trial and 5 uncontrolled studies. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. While the studies in the systematic review were generally of low quality and included only one trial comparing patients treated with GH with patients receiving no treatment, the review found that GH therapy was associated with an increase in height in patients with Noonan syndrome. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to short stature homeobox-containing gene (SHOX) deficiency who receive human GH, the evidence includes an RCT and systematic reviewan observational long-term study. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. An RCT found that children with short stature due to SHOX deficiency had significantly greater height velocity and height gain after 2 years when treated with GH vs no GH treatment. The long-term study reported that after 4 to 6 years of GH treatment, patients with SHOX deficiency may attain near-adult height. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have severe burns who receive human GH, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, hospitalizations, and treatment-related morbidity. Numerous RCTs evaluating GH for treatment of severe burns have been identified. Pooled analyses have found significantly shorter healing times and significantly shorter hospital stays with GH therapy than with placebo. Several RCTs have found significantly greater height gain in children with burns who received GH therapy vs placebo or no treatment. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AIDS wasting who receive human GH, the evidence includes observational studies, RCTs, and a systematic review with meta-analyses. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. A systematic review and meta-analysis found significant improvements in lean body mass with GH therapy vs placebo; several studies found improvements in quality of life. An RCT with a large sample size reported a significantly greater increase in exercise capacity with GH than with placebo. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short bowel syndrome on specialized nutritional support who receive human GH, the evidence includes RCTs and a meta-analysis. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. A pooled analysis of 3 small trials found significantly greater weight gain with GH therapy than with placebo and other studies found improved intestinal absorption in patients with short bowel syndrome receiving parenteral nutrition. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are small for gestational age who receive human GH, the evidence includes RCTs and a meta-analysis. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. A meta-analysis found that GH treatment in small for gestational age children resulted in significantly greater adult height compared with no treatment; however the clinical significance of the height difference between the study groups is unclear. There are few data on the psychological or functional outcomes associated with this additional gain in height. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have altered body habitus related to antiretroviral therapy for HIV infection who receive human GH, the evidence includes case series and an RCT. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The RCT measured the effect of low-dose GH on intermediate outcomes (inflammation markers). Case series data are insufficient for drawing conclusions about the impact of GH treatment on health outcomes in HIV-infected patients with altered body habitus related to antiretroviral therapy. Controlled studies reporting relevant outcomes are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have idiopathic short stature who receive human GH, the evidence includes RCTs and systematic reviews. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Systematic reviews have found that GH treatment may increase height gain for children with idiopathic short stature, but the difference in height gain may not be clinically significant. The available studies did not follow treated patients long enough to determine the ultimate impact of GH on final adult height. RCTs have not found that short stature is associated with psychological problems, contrary to the expectations of some advocates. In addition, the available trials have not reported a correlation between increases in height and improvements in psychological functioning. Moreover, this group of children is otherwise healthy and there are potential risks to GH therapy in childhood. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have "genetic potential" (i.e., lower than expected height percentiles based on parents’ height) who receive human GH, the evidence includes no clinical trials. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. No published literature was identified on GH therapy as a treatment of children with "genetic potential." The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have precocious puberty who receive human GH plus gonadotropin-releasing hormone (GnRH), the evidence includes a systematic review, an RCT and a comparative case series. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. While the systematic review included RCTs and clinical controlled trials, only 1 RCT and 4 clinical controlled trials provided data for the meta-analyses of final height, difference in final height and targeted height, and height gain. The meta-analyses reported statistically significant gains of several centimeters for patients who received the combination therapy for at least 1 year compared with patients receiving GnRH alone. However, no studies have reported on the impact of short stature on functional or psychological outcomes in this population. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are older adults with age-related growth hormone deficiency who receive human GH, the evidence includes a systematic review (TEC Assessment). Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The TEC Assessment concluded there is a lack of evidence that GH therapy in older adults improves health outcomes. No subsequent controlled studies were identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have cystic fibrosis who receive human GH, the evidence includes RCTs and a systematic review. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The RCTs were heterogenous and reported various outcomes. None of the systematic reviews pooled results for outcomes such as frequency of intravenous antibiotic treatment, quality of life, and bone fracture. The single pooled outcome (number of hospitalizations) was significantly lower in patients receiving GH therapy vs no treatment or placebo. Across the trials, GH was found to improve intermediate outcomes such as height and weight; however, clinically meaningful outcomes relating to lung function were not consistently improved with GH. The evidence is insufficient to determine the effects of the technology on health outcomes.

Background
Human growth hormone (GH), also known as somatotropin, is synthesized in somatotropic cells of the anterior lobe of the pituitary gland. Growth hormone deficiency (GHD) can occur for various conditions, such as:

Pituitary tumor.
Pituitary dysfunction due to prior surgery or radiation treatment.
Extrapituitary tumor.
Sarcoidosis and/or other infiltrating disorders.
Idiopathic.

GHD in children is manifested primarily by short stature. In adults, as well as in some children, other abnormalities associated with GHD are often evident. They include changes in body composition, higher levels of low-density lipoprotein cholesterol, lower bone density and a decreased self-reported quality of life compared with healthy peers. Some evidence has suggested that there may be increases in cardiovascular disease and overall mortality, but it is less clear whether GHD causes these outcomes.

Beginning in 1985, recombinant human growth hormone (rhGH) has been marketed for a variety of Food and Drug Administration FDA)-labeled indications (see Table 1).

Major points of controversy are what defines "inadequate secretion of normal endogenous growth hormone" and what constitutes "growth failure." Before the availability of biosynthetic GH, GH was rationed to children with classic GHD, as defined by a subnormal response (< 10 ng/mL, approximately, depending on GH assay) to GH provocation tests. However, the ready supply of GH has created interest in expanding its use to short-stature children without classic GHD, often referred to as partial GHD, neurosecretory GH dysfunction, constitutional delay in growth and development or idiopathic short stature. "Classic" GHD is suggested when the abnormal growth velocity (typically < 10th percentile) or height is more than 2 standard deviation score (SDS) below the current population mean, in conjunction with a chronologic age that is greater than the height age and bone age. Practically, interest in broadening the use of GH to non-GHD children has resulted in GH evaluation in many children who are simply below the 3rd percentile in height, with or without an abnormal growth velocity.

These broadened patient selection criteria have remained controversial due to uncertainties in almost every step in the diagnosis and treatment process — selection of patients to be tested, limitations in the laboratory testing for GH, establishment of diagnostic cutoffs for normal versus abnormal GH levels, availability of the laboratory tests to predict response to GH therapy, changes in growth velocity due to GH therapy, whether resulting final height is significantly improved and whether this improvement is clinically or emotionally significant for the patient. In addition, there are many ethical considerations regarding GH therapy, most prominently appropriate informed consent when the therapy is primarily requested by parents due to their particular psychosocial concerns about height.

In 2001, somatropin (Genotropin) received an FDA-labeled indication for treatment of pediatric patients born small for gestational age who failed to show catch-up growth by age 2 years. Most children born small for gestational age normalize their stature during infancy, but about 15% maintain an exceptionally short stature at least throughout childhood. Epidemiologic surveys have suggested that the average adult height of men and women who did not exhibit catch-up growth as children is 5 feet, 6 inches, in men and 5 feet, 1 inch, in women. GH has been investigated in these children, based in part on the hypothesis that a GH resistance is a possible etiology of the growth retardation. In 2003, FDA approved a rhGH product for use in non-GH-deficient short stature, defined by the manufacturer as a height SDS of -2.25 below the mean. This indication for GH is the first indication based on short stature alone, without an underlying etiology.

OUTCOME MEASURES IN GH RESEARCH
The most common outcome measure reported in GH research is change in height. For some situations, such as in patients with documented GHD or genetic disorder and short stature, improvements in height alone may be a sufficient outcome measure. However, in most situations, a change in height is not in itself sufficient to demonstrate that health outcomes are improved. There is insufficient evidence to establish that short stature is associated with substantial impairments in psychological functioning or quality of life, or that increases in height improve these parameters. Similarly, improvements in other measures of body composition (e.g., muscle mass, muscle strength) are not in themselves sufficient to establish that health outcomes are improved. Therefore, for most conditions in this literature review, changes in other outcome measures, (e.g., functional status, quality of life, disease-specific clinical outcomes) are necessary to demonstrate an improvement in health outcomes.

Regulatory Status
Several formulations of human GH have received FDA approval for various indications (see Table 1).

There are phase 2 and phase 3 trials including children and adults that are currently ongoing, evaluating new GH formulations that are administered weekly rather than daily.^1-3The new long-acting formulations have not received FDA approval at this time.

Table 1: FDA-Approved Indications by Product

Indications	Genotropin (Pfizer)	Humatrope (Lilly)	Norditropin (Novo-Nordisk)	Nutropin (Genentech)	Saizen (Serono)	Serostim (Serono)	Tev-Tropin Zomactonª (Ferring)	Zorbtive (Serono)	Omnitrope (Sandoz)
Growth failure, pediatrics patients with inadequate endogenous GH	yes	yes	yes	yes	yes		yes		yes
Replacement therapy in adults with GH deficiency	yes	yes	yes	yes	yes				yes
Growth failure due to Prader-Willi syndrome	yes								yes
Growth failure associated with chronic renal insufficiency				yes
Short stature due to Turner's syndrome (45, XO)	yes	yes	yes	yes					yes
Short stature in pediatrics patients with Noonan syndrome			yes
Short stature in pediatrics patients with SHOX deficiency		yes
HIV wasting or cachexia						yes
Treatment of short bowel syndrome								yes
Children born small for gestational age, who fail to show catch-up growth by age 2 y	yes	yes	yes						yes
Short stature (height x SDS < -2.25) in non-GHD pediatrics patients	yes	yes		yes					yes

FDA: Food and Drug Administration; GH: growth hormone; GHD: growth hormone deficiency; SDS: standard deviation score; SHOX; short stature homeobox-containing gene.
ª In March 2015, FDA approved a name change for Tev-Tropin; Tev-Tropin in now known as Zomacton.

Policy
Recombinant human growth hormone (GH) therapy may be considered MEDICALLY NECESSARY for the following patients (see specific patient selection criteria in the Policy Guidelines section):

Infants with proven growth hormone deficiency (GHD) who meet the following criteria:
1. Infant is < 4 months of age AND has suspected GH deficiency based on clinical presentation (e.g., persistent neonatal hypoglycemia, persistent or prolonged neonatal jaundice/elevated bilirubin, male infant with microgenitalia, midline anatomical defects, failure to thrive, etc.) OR
2. History of neonatal hypoglycemia associated with pituitary disease OR
3. Diagnosis of panhypopituitarism OR
4. Diagnosis of pediatric GH deficiency as confirmed by definition below:
  1. Height is documented by one of the following (utilizing age and gender growth charts related to height): Height is > 2.0 standard deviations [SD] below midparental height OR Height is > 2.25 SD below population mean (below the 1.2 percentile for age and gender) OR
  2. Growth velocity is > 2 SD below mean for age and gender OR
  3. Delayed skeletal maturation of > 2 SD below mean for age and gender (e.g., delayed > 2 years compared with chronological age) AND
Children
1. is male with Bone age < 16 years or Patient is female with Bone age < 14 year AND
2. Patient has undergone two of the following provocative GH stimulation tests: Arginine, Clonidine, Glucagon, Insulin or Levodopa with Both GH response values are < 10 mcg/L OR
3. Patient is < 1 year of age AND One of the following is below the age and gender adjusted normal range as provided by the physician's lab:
  1. Insulin-like Growth Factor 1 (IGF-1/Somatomedin-C)
  2. Insulin Growth Factor Binding Protein-3 (IGFBP-3)
Children with height below the 3rd percentile for chronologic age with chronic renal insufficiency
Patients with AIDS wasting who meet the following criteria:
1. One of the following:
  1. Unintentional weight loss of > 10% over the last 12 months OR
  2. Unintentional weight loss of > 7.5% over the last 6 months OR
  3. Loss of 5% body cell mass (BCM) within 6 months OR
  4. Body mass index (BMI) < 20 kg/m^2 OR
  5. All of the following
    - Patient is male with BCM < 35% of total body weight and BMI < 27 kg/m^2OR
    - Patient is female with BCM < 23% of total body weight and BMI < 27 kg/m^2 AND
2. Nutritional evaluation since onset of wasting first occurred AND
3. Patient has not had weight loss as a result of other underlying treatable conditions (e.g., depression, mycobacterium avium complex, chronic infectious diarrhea, or malignancy with the exception of Kaposi's sarcoma limited to skin or mucous membranes) AND
4. Anti-retroviral therapy has been optimized to decrease the viral load
Adults with proven GHD wasting who meet one of the following criteria:
1. Patient has undergone two of the following GH stimulation tests and have Two of the corresponding peak GH values:
  1. ITT less than or equal to 5 mcg/L
  2. Glucagon less than or equal to 3 mcg/L
  3. Macimorelin less than 2.8 ng/mL 30, 45, 60 and 90 minutes following macimor
2. Documented deficiency of three of the following anterior pituitary hormones AND IGF-1/Somatomedin-C level is below the age and gender adjusted normal range as provided by the physician's lab
  1. Prolactin
  2. ACTH
  3. TSH
  4. FSH/LH
Patients with Turner syndrome (female with Bone age < 14 years)
Children with growth failure due to Prader-Willi syndrome, who do not have the following contraindications: history of upper airway obstruction or sleep apnea or severe respiratory impairment
Patients with short stature due to Noonan syndrome (Patient is male with Bone age < 16 years or Patient is female with Bone age < 14 year AND Height is below the 5th percentile on growth charts for age and gender)
Promotion of wound healing in burn patients
Prevention of growth delay in children with severe burns
Patients with short bowel syndrome receiving specialized nutritional support in conjunction with optimal management of short bowel syndrome
Children with short stature due to SHOX (short stature homeobox-containing gene) deficiency wasting who meet one of the following criteria:
1. Diagnosis of pediatric growth failure with short stature homeobox (SHOX) gene deficiency as confirmed by genetic testing
2. Patient is male with Bone age < 16 years or Patient is female with Bone age < 14 years

The following indications approved by the Food and Drug Administration (FDA) are considered NOT MEDICALLY NECESSARY:

Pediatric patients born small for gestational age who fail to show catch-up growth by age 2 years
Children with height standard deviation score of -2.25 or below without documented GHD.

Recombinant human growth hormone is investigational/unproven therefore considered NOT MEDICALLY NECESSARY for all other applications including, but not limited to, the following:

Constitutional delay (lower than expected height percentiles compared with target height percentiles and delayed skeletal maturation when growth velocities and rates of bone age advancement are normal)
In conjunction with gonadotropin-releasing hormone analogues as a treatment of precocious puberty
GH therapy in older adults without proven deficiency
Anabolic therapy (except for AIDS) provided to counteract acute or chronic catabolic illness (e.g., surgery outcomes, trauma, cancer, chronic hemodialysis, chronic infectious disease) producing catabolic (protein wasting) changes in both adult and pediatric patients
Anabolic therapy to enhance body mass or strength for professional, recreational, or social reasons
Glucocorticoid-induced growth failure
Short stature due to Down syndrome
Treatment of altered body habitus (e.g., buffalo hump) associated with antiviral therapy in HIV-infected patients
Treatment of obesity
Treatment of cystic fibrosis
Treatment of idiopathic dilated cardiomyopathy
Treatment of juvenile idiopathic or juvenile chronic arthritis
Treatment of children with "genetic potential" (i.e., lower than expected height percentiles based on parents’ height)

Policy Guidelines
The numbered guidelines below correspond to the indications listed in the Policy section above.

MEDICALLY NECESSARY INDICATIONS

Both children and adults (see No. 4, below) with proven growth hormone deficiency (GHD) are considered appropriate candidates for growth hormone (GH) therapy.
- For adults, proven GHD is defined as:
1. - An abnormal response to TWO provocative stimulation tests, such as L-dopa, clonidine, glucagons, arginine, growth hormone‒releasing hormone (GH-RH), or insulin. The insulin tolerance test is considered the best predictor of GHD; however, this test is contraindicated in patients with seizures or coronary artery disease. A provocation test using arginine and GH-RH is also acceptable and is considered more stringent than tests using arginine alone or levodopa alone. Although an abnormal GH response has been traditionally defined as less than 10 ng/mL, different tests have different potencies, and the cutoff is likely to be lower when using monoclonal-based GH assays and recombinant human GH reference preparations. Twenty-four-hour continuous measurements of GH, serum levels of insulin-like growth factor-I (IGF-I), or serum of levels insulin-like growth factor‒binding protein are considered inadequate to document GHD.
  - An abnormal response to ONE provocative stimulation test in patients with defined central nervous system pathology, history of irradiation, multiple pituitary hormone deficiency, or a genetic defect
  - Low IGF-I concentration in patients with complete hypopituitarism.
- For children, no criteria have been established for the laboratory diagnosis of GHD, and criteria may vary regionally. The recommended dosage for children with GHD is 0.3 mg/kg/wk, divided into daily or 6 times per week injections. In children, GH therapy is typically discontinued when the growth velocity is less than 2 cm per year, when epiphyseal fusion has occurred, or when height reaches the 5th percentile of adult height.
Chronic renal insufficiency is defined as a serum creatinine of greater than 1.5 mg/dL (or 1.4 for women, 1.7 for men) or a creatinine clearance of 75 mL/min per 1.73 m²or less. In patients with chronic renal failure undergoing transplantation, GH therapy is discontinued at the time of transplant or when the growth velocity is less than 2 cm per year, when epiphyseal fusion has occurred, or when the height reaches the 5th percentile of adult height.
AIDS wasting is defined as a weight loss of more than 10% of baseline that cannot be explained by a concurrent illness other than HIV infection. Patients treated with GH must simultaneously be treated with antiviral agents. Therapy is continued until this definition is no longer met.
Adults with GHD are defined as in item 1 above. Only about 25% of those children with documented GHD will have GHD as adults. Therefore, once adult height has been achieved, subjects should be retested for GHD to determine if continuing replacement therapy is necessary. These transition patients who require further treatment are usually started at doses of 0.4 to 0.8 mg/d, and titrated to maintenance doses of 1.2 to 2.0 mg/d. Adults with GHD not related to idiopathic deficiency of childhood (e.g., pituitary tumor, pituitary surgical damage, irradiation, trauma) are usually started at 0.1 to 0.3 mg/d; the dose is titrated to clinically desired end points (improved body composition, quality of life, reduction in cardiovascular risk factors), usually resulting in maintenance doses of 0.2 to 0.5 mg/d for men and 0.4 to 1.0 mg/d for women. The Food and Drug Administration (FDA) cautions that the safety and effectiveness of GH therapy in adults ages 65 and older has not been evaluated in clinical studies. Therefore, elderly patients may be more sensitive to the action of GH therapy and may be more prone to develop adverse reactions.
Turner syndrome is defined as a 45,XO genotype.
Prader-Willi syndrome is a genetic disorder characterized by a microdeletion in the long arm of chromosome 15. Clinically, the syndrome presents as a complex multisystem disorder characterized by excessive appetite, obesity, short stature, characteristic appearance, developmental disability, and significant behavioral dysfunction. GHD has been demonstrated in most tested patients with Prader-Willi syndrome.
- Sleep studies are recommended prior to initiation of GH therapy for obese pediatric patients with Prader-Willi syndrome. If signs of upper airway obstruction and sleep apnea occur, GH should not be administered. If during treatment, patients develop signs of upper airway obstruction or new sleep apnea, treatment should be interrupted.
GH therapy for burn patients should be limited to those patients with third-degree burns.
Children with severe burns have been successfully treated with recombinant GH 0.05 to 0.2 mg/kg/d during acute hospitalization and for up to 1 year after burn.
GH for patients with short bowel syndrome should be limited to patients receiving specialized nutritional support in conjunction with optimal management of short bowel syndrome. Specialized nutritional support may consist of a high-carbohydrate, low-fat diet adjusted for individual patient requirements. Optimal management may include dietary adjustments, enteral feedings, parenteral nutrition, fluid, and micronutrient supplements. Zorbtive is administered daily at 0.1 mg/kg subcutaneously up to 8 mg/d. Administration of somatropin (Zorbtive) for more than 4 weeks has not been adequately studied per the FDA indications.

NOT MEDICALLY NECESSARY INDICATIONS

Pediatric patients born small for gestational age. In the data submitted to FDA as part of the approval process, the mean height of enrolled patients was at least 2 standard deviations (SD) below the mean. Absence of catch-up growth was defined as a height velocity below 1 standard deviation score (SDS), adjusted for age.
Pediatric patients with short stature. "Short stature" has been defined by the American Association of Clinical Endocrinologists and the Growth Hormone Research Society as height more than 2 SD below the mean for age and sex. The FDA-approved indication is for children with a height SDS of -2.25 below the mean. Using this proposed definition, approximately 1.2% of all children would be defined as having idiopathic short stature and considered potentially treatable under these indications. Note that this indication is considered not medically necessary.

Benefit Application
BlueCard^®/National Account Issues
Human growth hormone may be adjudicated under the Drug Benefit as an injectable.

State or federal mandates may require coverage eligibility for drugs used according to their FDA-labeled indications. In this policy, two FDA-labeled indications are considered “not medically necessary,” i.e., pediatric patients born small for gestational age and pediatric patients with short stature.

Rationale
Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function — including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical uses of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

SAFETY OF GROWTH HORMONE TREATMENT
Adverse events can occur with growth hormone (GH) treatment. In children, increased rates of skeletal problems (e.g., worsening of scoliosis) can occur in association with a rapid growth spurt. In adults, arthralgias, edema, and carpal tunnel syndrome are common. Less common adverse events include pancreatitis and gynecomastia.^4,5 There is also concern that GH treatment may increase the rate of malignancy, particularly de novo leukemia, in patients without risk factors. However, to date, there is insufficient evidence of a causative relation between GH treatment and malignancy rates.

Swerdlow et al. (2017) published results from the Safety and Appropriateness of Growth Hormone Treatments in Europe study, which compared the risk of cancer mortality and cancer incidence among patients receiving GH therapy with national population rates.⁶ For the cancer mortality analysis, the cohort consisted of 23,984 patients from 8 European countries. For the cancer incidence analysis, only those patients from countries with highly complete cancer registries (Belgium, Netherlands, Sweden, Switzerland, United Kingdom) were included (n = 10,406). Over 50% received GH treatment due to “isolated growth failure,” defined as growth hormone deficiency (GHD), idiopathic short stature, and prenatal growth failure. Other common diagnoses leading to GH treatment included: Turner syndrome, pituitary hormone deficiency, and central nervous system tumor. For the cancer mortality cohort, mean follow-up was 17 years, mean age at follow-up was 27 years, and there were 251 cancer deaths. For the cancer incidence cohort, mean follow-up was 15 years, mean age at last follow-up was 26 years, and there were 137 incident cancers. For patients whose initial diagnosis was “isolated growth failure,” overall cancer risk was not elevated. For patients whose initial diagnosis was not cancer, neither cancer mortality nor cancer incidence was related to age of treatment initiation and duration of treatment.

Several publications on the safety of GH therapy have used French registry data and vital statistics. Analysis of long-term mortality after GH treatment was conducted by Carel et al. (2012).⁷ A total of 6,928 children were included in the study. Indications for GH therapy included idiopathic isolated GHD (n = 5162), neurosecretory dysfunction (n = 534), idiopathic short stature (n = 871), and born small for gestational age (n = 335). The mean dose of GH used was 25 μg/kg/d, and the mean treatment duration was 3.9 years. Patients were followed for a mean of 17.3 years. As of September 2009, follow-up data on vital status were available for 6,558 (94.7%) of participants. Ninety-three (1.42%) of the 6,558 individuals had died. The mortality rate was significantly higher in patients treated with GH than would be expected on the basis of year, sex, or age (standardized mortality ratio, 1.33; 95% confidence interval [CI], 1.08 to 1.64). Examination of the causes of death found a significant increase in mortality due to circulatory system diseases. In addition, there was a significant increase in the number of deaths due to bone tumors (3 observed deaths vs 0.6 expected deaths) but no other types of cancers or overall cancer deaths. There was also a significant increase in the number of deaths due to cerebral or subarachnoid hemorrhage (4 observed deaths vs 0.6 expected).

Poidvin et al. (2014) reported on the same data, focusing on risk of stroke in adulthood among childhood users of GH therapy.⁸ This analysis included 6,874 children with idiopathic isolated GHD or short stature; mean length of follow-up was 17.4 years. There were 11 (0.16%) validated cases of stroke and the mean age at the time of stroke was 24 years. Risk of stroke was significantly higher in adults who had used GH than in general population controls. Stroke risk was also compared with general population controls.

Standard incidence ratios were 2.2 (95% CI, 1.3 to 3.6) compared with registry data from Dijon and 5.3 (95% CI, 3.0 to 8.5) using Oxford registry data. The increased risk was largely for hemorrhagic stroke (8/11 cases), and this elevated risk persisted when the 3 patients who had been small for gestational age were excluded from the analysis. In all of the analyses from this research team, there were a small number of events (ie, deaths or stroke), and thus conclusions from these data are not definitive on the long-term safety of GH therapy.

According to drug prescribing information, GH therapy use has been associated with sudden death in children with Prader-Willi syndrome.^9,10 These deaths occurred among children who were severely obese or had severe respiratory impairment; these markers are now considered contraindications to GH treatment in patients with Prader-Willi syndrome.

GROWTH HORMONE DEFICIENCY
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with proven GHD.

The question addressed in this evidence review is: Does use of human GH improve the net health outcomes in individuals with proven GH?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with proven GHD.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat GHD: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up at 1 year is of interest to monitor outcomes.

Setting
Patients with GHD are actively managed by endocrinologists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.

GHD in Children
In children with GHD, treatment has been found to increase growth velocity and final height. Root et al. (1998) followed approximately 20,000 children for 9 years as part of the National Cooperative Growth Study.¹¹ Growth velocity improved compared with pretreatment values, and this improvement was maintained for at least 4 years. For children treated for at least 7 years, improvements in the mean height standard deviation score (SDS) ranged from 1.3 to 2.5, depending on the specific underlying condition. If treatment is started at an early age, most children can achieve a final height close to that expected from parental height. In a study of 1258 patients in the Pfizer International Growth Database, Reiter et al. (2006) found the standard deviation (SD) for differences between the final height achieved and the midrange of predicted height from parental values ranged between -0.6 and +0.2, depending on the specific underlying condition.¹²

GHD in Adults
In adults with GHD, evidence from RCTs has shown that treatment leads to increases in lean body mass and decreases in body fat.¹³

Systematic Reviews
Meta-analyses of RCTs have shown evidence for increases in muscle strength and exercise capacity, although these findings were not robust across all studies.¹⁴^,15 There is also evidence from meta-analyses that GH therapy is associated with increased bone mineral density (BMD) in adults with GHD.^16,17 For example, a meta-analysis by Barake et al. (2014) identified 9 placebo-controlled randomized trial with at least 1-year follow-up on the effect of daily GH therapy on BMD.¹⁷ Analysis of RCT data found a statistically significant increase in BMD of the lumbar spine and femoral neck in patients with GHD who received GH therapy for more than 2 months. Change in BMD ranged from 1% to 5% at the spine and 0.6% to 4% at the femoral neck. A limitation of the Barake analysis is that data were not available on fracture rates, a clinically important outcome. The evidence on other outcomes (e.g., quality of life, lipid profiles, cardiovascular disease, total mortality) has been inconsistent and insufficient to determine whether these outcomes improved with treatment.^18,19,20,21

Observational Studies
Ishii et al. (2017) published an industry-funded, multicenter, observational study of GH therapy for adults with GHD.²² One hundred sixty-one patients were eligible for quality of life analysis using the Adult Hypopituitarism Questionnaire (AHQ). For male and female patients combined, AHQ scores were improved from baseline in both psycho-social and physical domains. Women had significantly lower AHQ scores than men throughout, however, the net changes in AHQ scores did not differ significantly between men and women (psycho-social domain: 4.90 vs 4.36; p = 0.833; physical domain: 5.04 vs 2.29; p = 0.213; respectively), despite an increase in GH dose such that insulin-like growth factor-1 levels for women reached that of men. The study was limited due to loss to follow-up, data collection being on patient recall, the observational design, and lack of a control group.

Section Summary: Growth Hormone Deficiency
Large cohort studies, RCTs, and meta-analyses have found that, for children with documented GHD and clinical manifestations such as short stature, GH replacement has improved growth velocity and final height achieved. In addition, studies have shown that GH therapy can ameliorate the secondary manifestations of GHD and may increase lean muscle mass and BMD seen primarily in older children and adults.

SHORT STATURE DUE TO PRADER-WILLI SYNDROME
Prader-Willi syndrome is a rare neurodevelopmental disorder characterized by muscular hypotonia, hypogonadism, short stature, obesity, psychomotor delay, neurobehavioral abnormalities, and cognitive impairment. Most children with Prader-Willi syndrome have hypothalamic dysfunction and are GH- deficient. The value of testing for GHD before treatment in these patients is questionable. None of the clinical studies selected patients for treatment based on presence or absence of GHD, nor were results reported separately for those with or without GHD. Information from the product label indicates that the height SDS for Prader-Willi syndrome children in the clinical studies was -1.6 or less (height was in the 10th percentile or lower).

Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with short stature due to Prader-Willi syndrome.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in children with short stature due to Prader-Willi syndrome?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is children with short stature due to Prader-Willi syndrome.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat Prader-Willi syndrome: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up at 8 years is of interest to monitor outcomes.

Setting
Patients with short stature due to Prader-Willi syndrome are actively managed by endocrinologists, occupational and behavioral specialists, and geneticists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Randomized Controlled Trials
Several RCTs in children have shown improvements in health outcomes with GH treatment. For example, Kuppens et al. (2016) published results from a 2-year crossover, blinded, placebo-controlled randomized trial designed to investigate the effects of GH on body composition in young adults with Prader-Willi syndrome who were treated with GH during childhood and had attained adult height.²³ Patients (N = 27) were stratified by sex and body mass index and randomized to GH injections once daily or placebo injections. After 1 year, the patients received the alternate treatment. Every 3 months, fat mass and lean body mass were measured by dual-energy x-ray absorptiometry. GH treatment resulted in lower mean fat mass (-17.3%) and higher lean body mass (+3.5%) compared with placebo.

Lo et al. (2015) conducted a 2-year RCT of GH therapy vs no treatment followed by a cohort study of the children on GH therapy for an additional 6 years.²⁴ The trial included 42 prepubertal children (age range, 3.5-14 years); children were not selected based on GHD status. The primary outcome was the impact of GH treatment on behavior, measured by 2 validated parent questionnaires: the Developmental Behavior Checklist (DBC) and the Children’s Social Behavior Questionnaire (CSBQ). At the end of the 2-year RCT, there were no significant differences in DBC and CSBQ scores between the GH-treated and no-treatment groups. Findings were similar at the end of the 8-year follow-up period.

Moreover, an RCT by Reus et al. (2013) found that the addition of GH therapy to physical training resulted in greater improvements in motor development than physical training alone.²⁵ This 2-year, single-blind trial included 22 children newly diagnosed with Prader-Willi syndrome (mean age, 12.9 months). GHD status was not considered in the study eligibility criteria. Outcomes were evaluated every 3 months, and multiple regression analysis was conducted to evaluate whether GH had an impact on motor development over time. Among the results was a finding that GH had statistically significant interaction effects for a model predicting motor development age using the Alberta Infant Motor Scale.

An earlier RCT by Festen et al. (2008) included 42 infants and 49 prepubertal children (age range, 3 – 14 years).²⁶ GHD status was not part of the study eligibility criteria. The study found that GH treatment significantly improved height, body mass index, head circumference, and body composition. In 2012, the same investigators published cognitive outcomes in children participating in this trial.²⁷ During the 2-year randomized study, mean total IQ score and subtests did not change significantly from baseline in GH- treated children. In untreated children, there was no significant change in total IQ score, but scores on 2 of 3 subtests significantly declined from baseline.

Case Reports
There have been numerous case reports of sudden unexpected death in Prader-Willi syndrome patients undergoing GH therapy.^28,29,30 Causes of death included respiratory insufficiency and sleep apnea, suggesting that GH therapy may exacerbate respiratory impairment in patients with Prader-Willi syndrome. The product labels for GH treatments, therefore, warn that children with Prader-Willi syndrome be evaluated for signs of upper airway obstruction and sleep apnea prior to initiation of treatment and that treatment should be discontinued if these signs occur.^9,10

Section Summary: Short Stature due to Prader-Willi Syndrome
Several RCTs have found improvements in height, body mass index, head circumference, and motor development in children with Prader-Willi syndrome treated with GH. GH treatment was not found to significantly change problem behavior or total IQ. In a blinded crossover RCT, patients with Prader-Willi syndrome, who were treated with GH as children and had attained adult height experienced lower fat mass and higher lean body mass when treated with GH compared with placebo. Studies have found increased risk of adverse events in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment, and thus these are contraindications.

SHORT STATURE DUE TO CHRONIC RENAL INSUFFICIENCY
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with short stature due to chronic renal insufficiency.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with short stature due to chronic renal insufficiency?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with short stature due to chronic renal insufficiency.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat short stature due to chronic renal insufficiency: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up at 9 years is of interest to monitor outcomes.

Setting
Patients with short stature due to chronic renal insufficiency are actively managed by endocrinologists, occupational and behavioral therapists, and nephrologists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
Wu et al. (2013) published a systematic review of RCTs evaluating the impact of GH therapy on height outcomes following renal transplant in children ages 0 to 18 years.³¹ Five trials (total N = 401 participants) met reviewers’ inclusion criteria (RCTs including renal allograft recipients between 0 and 18 years old). Trials were published between 1996 and 2002. A meta-analysis found significantly improved height velocity at the end of a trial in children taking GH compared with a no-treatment control group. At the beginning of the year, both groups had a negative height SDS, with no statistically significant differences between groups. After 1 year, the pooled mean difference (MD) in height SDS was 0.68 (95% CI, 0.25 to 1.11; p = 0.002) in favor of the GH group. There were no statistically significant differences between groups in the rate of rejection episodes or in renal function.

Previously, Hodson et al. (2012) published a Cochrane review of RCTs evaluating GH treatment in children with chronic kidney disease.³² To be included in the review, trials needed to include children 18 years old or younger who were diagnosed with chronic kidney disease and were predialysis, on dialysis, or posttransplant. In addition, trials had to compare GH treatment with placebo, no treatment, or a different GH regimen, and needed to include height outcomes. Seven RCTs with 809 children met reviewers’ criteria. Study entry criteria varied (e.g, ranging from < 3rd percentile for chronologic age to < 50th percentile for chronologic age). Overall, treatment with GH (28 IU/m2/wk) compared with placebo or no specific therapy resulted in a statistically significant increase in height SDS at 1 year (8 studies; MD = 0.82; 95% CI, 0.56 to 1.07). Moreover, a pooled analysis of 7 studies found a significant increase in height velocity at 1 year in the group receiving GH treatment compared with control (MD = 3.88 cm/y; 95% CI, 3.32 to 4.44 cm/y).

Randomized Controlled Trials
An example of an individual RCT is Hokken-Koelega et al. (1991), conducted in the Netherlands.³³ This double-blind, placebo-controlled crossover trial included 20 prepubertal children with severe growth retardation and chronic renal failure. Entry criteria included height velocity less than the 25% percentile for chronologic age. Patients received 6 months of subcutaneous injection of GH (4 IU/m2/d) before or after 6 months of placebo injection. There was a 2.9 cm greater increase in height velocity per 6 months with GH than with placebo. Long-term follow-up data on children in this and other Dutch RCTs (maximum of 8 years of treatment) were published in 2000.³⁴ GH treatment resulted in significant improvement in the height SDS compared with baseline scores (p < 0.001). Moreover, the mean height SDS reached the lower end (-2 SDS) of the normal growth chart after 3 years of treatment. Puberty began at a median age within the normal range for girls and boys, and GH therapy did not significantly affect parathyroid hormone concentrations, and there were no radiologic signs of renal osteodystrophy.

Nonrandomized Studies
Primary outcomes in most studies of GH for the treatment of children with chronic kidney disease are height or height velocity. A case-control study by Bizzarri et al (2018) compared the final height of children treated (n = 68) and not treated (n = 92) with GH who had chronic kidney disease.³⁵ Mean follow-up was 9 years. Among cases, the mean duration of GH therapy was 4 years. Height SDS significantly improved from baseline to final height in GH-treated children, while there was a slight but nonsignificant decrease in height SDS among non-GH-treated children. However, final height SDS did not differ significantly between treated and nontreated children (p = 0.3). The reason for no difference in final height might have been that the nontreated children had a significantly higher height SDS at baseline compared with the treatment group. This difference might be why GH treatment was not initiated in the control group.

Section Summary: Short Stature due to Chronic Renal Insufficiency
Numerous RCTs and systematic reviews of RCTs have found significantly increased height and height velocity in children with short stature associated with chronic renal insufficiency who were treated with GH therapy compared with another intervention. There were no significant increases in adverse events related to renal function.

SHORT STATURE DUE TO TURNER SYNDROME
Short stature is a characteristic of Turner syndrome, although the syndrome is not associated with GHD. Poor growth is evident in utero, and further deceleration occurs during childhood and at adolescence. The mean adult height for those with Turner syndrome is 58 inches (4 feet, 10 inches). FDA approvals for GH were based on the results of RCTs that included final adult height as the outcome. In one study, a group of patients with Turner syndrome given somatropin (Humatrope) at a dosage of 0.3 mg/kg/wk for a median of 4.7 years achieved a final height of 146.0 cm (57.5 in) compared with an untreated control group who achieved a final height of 142.1 cm (56 in).¹⁰

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with short stature due to Turner syndrome?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with short stature due to Turner syndrome.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat short stature due to Turner syndrome: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Treatment of an average 6 years is of interest to monitor outcomes.

Setting
Patients with short stature due to Turner syndrome are actively managed by endocrinologists, occupational and behavioral specialists, and geneticists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
Li et al. (2018) conducted a meta-analysis to determine the effect of recombinant human GH treatment on height outcomes in patients with Turner syndrome.³⁶ Eleven RCTs (total N = 1122 patients), published between 1986 and 2011, were identified for the analysis. Compared with controls, there was a significant increase in final height (mean difference [MD], 7.2 cm; 95% CI, 5.27 to 9.18 cm; p < 0.001), height SD (standardized mean difference [SMD], 1.22 cm; 95% CI, 0.88 to 1.56 cm; p < 0.001), and height velocity (MD = 2.68 cm/y; 95% CI, 2.34 to 3.02 cm/y; p < 0.001) for patients receiving GH. After 1 year, bone age increased slightly for the GH group (SMD = 0.32/y; 95% CI, 0.1 to 0.54/y; p = 0.004). The meta-analysis was limited by the small number of available studies and the lack of sufficient data on final height.

A Cochrane review by Baxter et al. (2007) identified 4 RCTs (total N = 365 patients) evaluating GH for treating Turner syndrome.³⁷ Studies included children who had not yet achieved final height, had treated children for at least 6 months, and compared GH with placebo or no treatment. Only 1 trial reported final height, so outcomes could not be pooled. A pooled analysis of 2 trials reported that short-term growth velocity was greater in treated than in untreated children (MD = 3 cm/y; 95% CI, 2 to 4 cm/y).

Nonrandomized Studies
In addition to short stature, individuals with Turner syndrome also exhibit craniofacial characteristics such as shorter and flattened cranial bases and inclined maxilla and mandible. A cross-sectional study by Juloski et al. (2016) compared the craniofacial morphology of 13 patients who had Turner syndrome treated using GH with 13 patients who had Turner syndrome not treated using GH.³⁸ Mean age of participants was 17 years. Individuals in the treatment group had received GH for a mean of 5.8 years. Comparisons of lateral cephalometric radiographs showed that GH therapy significantly increased linear measurements, mainly influencing posterior and anterior face height, mandibular height and length, and maxillary length. Angular measurements and facial height ratio did not differ significantly between groups.

Section Summary: Short Stature due to Turner Syndrome
Several RCTs have been published and/or are reported in FDA documents. Studies have found that GH therapy increases height outcomes (eg, final height, height velocity) in children with short stature due to Turner syndrome compared with placebo or no treatment. GH therapy has also been found to have a positive effect on craniofacial development.

SHORT STATURE DUE TO NOONAN SYNDROME
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with short stature due to Noonan syndrome. Noonan syndrome is associated with slow growth, starting in early childhood.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with short stature due to Noonan syndrome?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with short stature due to Noonan syndrome.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat short stature due to Noonan syndrome: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up to 3 years is of interest to monitor outcomes.

Setting
Patients with short stature due to Noonan syndrome are actively managed by endocrinologists, occupational and behavioral specialists, and geneticists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
Giacomozzi et al. (2015) published a systematic review of literature on the effect of GH therapy on adult height.³⁹ Included in the review were studies treating individuals with a diagnosis of Noonan syndrome with no other causes of short stature and a normal karyotype in females. In addition, studies had to follow patients for at least 3 years. Twenty-three studies were identified in a literature search conducted through April 2014, and 6 studies (total N = 177 patients) met the inclusion criteria; none were RCTs, one was controlled, and the rest prospective or retrospective cohort studies or case reports.

In the single controlled study (MacFarlane et al. [2001]⁴⁰), over the 3-year follow-up, the GH-treated group gained a mean of 3.3 cm more than the untreated group. Among the uncontrolled studies, 2 reported adult height. Mean height SDS was -2.8 (SD = 0.6) and mean adult height SDS was -1.4 (SD = 0.9). Two uncontrolled studies reported near-adult height, which was -2.1 (SD = 0.9). In addition, 2 studies reported a change in height SDS corresponding to 8.6 cm (SD = 5.9). Mean height gain in SDS ranged from 0.6 to 1.4 cm by national standards, and between 0.6 and 2.0 cm by Noonan standards. The data were limited by the paucity of controlled studies and lack of RCTs.

Section Summary: Short Stature due to Noonan Syndrome
Evidence consists of a systematic review including a controlled trial and 5 uncontrolled studies. The data were limited due to lack of comparative studies; however, the systematic review found that GH therapy is associated with an increase in height in patients with short stature due to Noonan syndrome.

SHORT STATURE DUE TO SHORT STATURE HOMEOBOX-CONTAINING GENE DEFICIENCY
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with short stature due to short stature homeobox-containing gene (SHOX) deficiency.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with short stature due to SHOX deficiency?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with short stature due to SHOX deficiency.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat short stature due to SHOX deficiency: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up to 5 years is of interest to monitor outcomes.

Setting
Patients with short stature due to SHOX deficiency are actively managed by endocrinologists, occupational and behavioral specialists, and geneticists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Randomized Controlled Trials
A health technology assessment by Takeda et al. (2010) assessed GH treatment of growth disorders in children identified an RCT evaluating GH therapy for children with short stature due to SHOX deficiency.⁴¹ This industry-sponsored, open-label multicenter trial was published by Blum et al. (2007).⁴² It included 52 prepubertal children age at least 3 years who had SHOX deficiency. Height requirements were less than the 3rd percentile of the local reference range or less than 10th percentile with height velocity less than the 25th percentile. Participants were randomized to 2 years of GH treatment (n = 27) or usual care (n = 25). The primary outcome was first-year height velocity. Fifty-one of 52 patients completed the trial. The first- year height velocity was 8.7 cm/y in the GH therapy group and 5.2 cm/y in the usual care group (p < 0.001). Height gain over the 2-year treatment period was 16.4 cm in the treatment group and 10.5 cm in the usual care group (p < 0.001). No serious adverse events were reported for either group. At the end of the randomized phase, all patients were offered GH.

Nonrandomized Studies
Benabbad et al. (2017) published long-term height results and safety data from patients in the Blum RCT (described above) and from a subset of patients with short stature due to SHOX deficiency from the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).⁴³ GeNeSIS was a prospective, multinational, open-label, pediatric surveillance program examining long-term safety and efficacy of GH. The subset of the GeNeSIS population with SHOX deficiency consisted of 521 patients. Forty-nine of the 52 patients in the RCT enrolled in the long-term study. Patients in both studies will be followed until they achieve near-adult (final) height. Final height was defined as attaining one of the following criteria: height velocity less than 2 cm/y, hand x-ray showing closed epiphyses, or bone age older than 14 years for boys or older than 16 years for girls. At the time of the analysis, 90 patients from GeNeSIS and 28 patients from the RCT reached near-adult height. For the GeNeSIS patients, mean age at GH treatment initiation was 11.0 years, mean age at near-adult height was 15.7 years, and GH treatment duration was 4.4 years. For the RCT patients, mean age at GH initiation was 9.2 years, mean age at near-adult height was 15.5 years, and GH duration was 6.0 years. The most common treatment- emergent adverse events reported in the GeNeSIS patients were: precocious puberty (2.6%) and arthralgia (2.4%). The most common treatment-emergent adverse events reported in the RCT patients were: headache (18.4%) and congenital bowing of long bones (18.4%).

Section Summary: Short Stature due to Short Stature Homeobox-Containing Gene Deficiency
An RCT found that children with short stature due to SHOX deficiency had significantly greater height velocity and significantly more height gain after 2 years when treated with GH vs no GH treatment. A long-term observational study reported that patients with SHOX deficiency were able to reach near-adult height after 4 to 6 years of GH treatment.

SEVERE BURNS
Clinical Context and Test Purpose
The purpose of human GH to treat or to prevent growth delay is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with severe burns.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with severe burns?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with severe burns.

Interventions
The therapy being considered is human GH to treat or to prevent growth delay.

Comparators
The following practice is currently being used to treat or prevent growth delay due to severe burns: standard wound care. Typical treatment for severe burns includes skin transplantation and grafting.

Outcomes
The general outcomes of interest are symptoms, hospitalizations, and treatment-related morbidity.

Timing
Follow-up at 2 years is of interest to monitor outcomes.

Setting
Patients with severe burns are actively managed by burn center specialists and orthopedic surgeons in an outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Treatment of Severe Burns
Systematic Reviews
A Cochrane review by Breederveld et al. (2012) included RCTs evaluating the impact of GH therapy on the healing rates of burn wounds.⁴⁴ Thirteen trials were identified that compared GH therapy with another intervention or to placebo. Six included only children, and seven involved only adults. Twelve studies were placebo-controlled. Findings of 2 studies reporting wound healing time in days were pooled. The mean healing time was significantly shorter in the GH-treated group than in the placebo group (MD = -9.07 days; 95% CI, -4.39 to -13.76). Reviewers also performed meta-analyses of studies that did not conduct survival analyses but did follow patients until their wounds healed. These analyses found significantly shorter healing time in patients who received GH therapy among adults (2 studies) and among children (2 studies). A pooled analysis of 5 studies did not find a statistically significant difference in mortality among patients receiving GH therapy and placebo (relative risk [RR], 0.53; 95% CI, 0.22 to 1.29). The mortality analysis likely was underpowered; the total number of deaths was 17. A pooled analysis of 3 studies involving adults found significantly shorter hospital lengths of stay in patients who received GH therapy compared with placebo (MD = -12.55 days; 95% CI, -17.09 to -8.00 days). In another pooled analysis, there was a significantly higher incidence of hyperglycemia in GH-treated patients than in controls (RR = 2.65; 95% CI, 1.68 to 4.16).

Randomized Controlled Trials
An RCT by Knox et al. (1995) measuring mortality included 54 adult burn patients who survived the first 7 postburn days.⁴⁵ Those patients showing difficulty with wound healing were treated with human GH and compared with those healing at the expected rate with standard therapy. Mortality of GH-treated patients was 11% compared with 37% for those not receiving GH (p = 0.027). Infection rates were similar in both groups.

Singh et al. (1998) studied 2 groups of patients (N = 22) with comparable third-degree burns; those who received GH had improved wound healing and a lower mortality rate (8% vs. 44%).⁴⁶ A placebo-controlled trial by Losada et al. (2002) found no benefit to GH with regard to length of hospitalization in 24 adults with severe burns.⁴⁷

Prevention of Growth Delay in Children With Severe Burns
Children with severe burns show significant growth delays for up to 3 years after injury. GH treatment in 72 severely burned children for 1 year after discharge from intensive care resulted in significantly increased height in a placebo-controlled, randomized, double-blinded trial.⁴⁸ Aili Low et al. (2001) also found that GH treatment in severely burned children during hospitalization resulted in significantly greater height velocity during the first 2 years after burn compared with a similar group of untreated children.⁴⁹

Section Summary: Severe Burns
Numerous RCTs evaluating GH for treatment of severe burns have been identified. Pooled analyses found significantly shorter healing times and significantly shorter hospital stays with GH therapy vs placebo. Several RCTs have found significantly greater height gains in children with burns who received GH therapy vs placebo or no treatment.

AIDS WASTING
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with AIDS wasting.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with AIDS wasting?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with AIDS wasting.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat AIDS wasting: treatment with different medications.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up at 12 weeks is of interest to monitor outcomes.

Setting
Patients with AIDS wasting are actively managed by HIV specialists and infectious disease specialists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
Moyle et al. (2004) published a systematic review and meta-analysis of controlled and uncontrolled studies on selected treatments of HIV wasting.⁵⁰ To be included, studies had to assess more than 10 patients and have a treatment duration lasting at least 2 weeks. Pooled analysis of 3 studies using GH therapy showed significant increases in lean body mass compared with placebo (MD = 3.1; 95% CI, 2.7 to 3.6). Pooled analysis of 6 studies reporting pre-post lean body mass measurements also showed significant increases following GH treatment (MD = 2.7; 95% CI, 1.4 to 3.7). Two studies evaluating GH treatment found statistically significant improvements in some measurements of quality of life after 12 weeks.

Randomized Controlled Trials
A double-blind RCT by Evans et al. (2005) included 700 patients with HIV-associated wasting.⁵¹ Patients were randomized to daily GH, alternate days of GH, or placebo. Patients assigned to daily GH had significantly greater increases in maximum exercise capacity (the primary outcome) than patients assigned to placebo.

Section Summary: AIDS Wasting
A systematic review and meta-analysis of the literature found significant improvements in lean body mass with GH therapy vs placebo and improvements in quality of life. A subsequent RCT with a large sample size found a significantly greater increase in maximum exercise capacity with GH treatment than with placebo.

SHORT BOWEL SYNDROME WITH SPECIALIZED NUTRITIONAL SUPPORT
Short bowel syndrome is experienced by patients who have had 50% or more of the small intestine removed. This procedure results in malnourishment because the remaining small intestine is unable to absorb enough water, vitamins, and other nutrients from food. The FDA label for somatropin (Zorbtive) indicates that GH has been shown in human clinical trials to enhance the transmucosal transport of water, electrolytes, and nutrients. According to the product label, the FDA’s approval for Zorbtive was based on the results of a randomized, controlled, phase 3 trial in which patients dependent on intravenous parenteral nutrition who received Zorbtive (either with or without glutamine) over a 4-week period had significantly greater reductions in the weekly total volume of intravenous parenteral nutrition required for nutritional support. However, the effects beyond 4 weeks were not evaluated nor were treatment locations (inpatient vs outpatient) identified.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with short bowel syndrome?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with short bowel syndrome on specialized nutritional support.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat short bowel syndrome: standard of care.

Outcomes
The general outcomes of interest are functional outcomes, health status measures, and treatment-related morbidity.

Timing
Follow-up at 4 weeks is of interest to monitor outcomes.

Setting
Patients with short bowel syndrome on specialized nutritional support are actively managed by endocrinologists, and dieticians in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
A Cochrane review by Wales et al. (2010) identified 5 RCTs evaluating GH therapy for treating short bowel syndrome.⁵² Studies evaluated GH with or without glutamine treatment. The primary outcome was change in body weight. A pooled analysis of 3 small trials (n = 30 patients) found a statistically significant difference in weight change when patients were treated with GH compared with placebo (MD = 1.7 kg; 95% CI, 0.7 to 2.6 kg; p < 0.001). Lean body mass, nitrogen absorption, and energy absorption also significantly increased in patients receiving GH therapy compared with controls.

Several published trials have also demonstrated improved intestinal absorption in short bowel syndrome patients receiving parenteral nutrition.^53,54 However, the Cochrane review and the studies noted that the effects of increased intestinal absorption were limited to the treatment period.⁵²^,54,55 Specialized clinics may offer intestinal rehabilitation for patients with short bowel syndrome; GH may be a component of this therapy.

Section Summary: Short Bowel Syndrome With Specialized Nutritional Support
A pooled analysis of 3 small RCTs found a significantly greater weight gain with GH therapy compared with placebo; others studies have found improved intestinal absorption on patients with short bowel syndrome receiving parenteral nutrition.

SMALL FOR GESTATIONAL AGE CHILDREN
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients who are small for gestational age in childhood.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in children who are small for gestational age?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is children who are small for gestational age.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat children small for gestational age: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Treatment of an average 7.3 years is of interest to monitor outcomes.

Setting
Children who are small for gestational age are actively managed by endocrinologists and primary care physicians in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
A meta-analysis of RCTs evaluating GH treatment for children born small for gestational age was published by Maiorana and Cianfarani (2009).⁵⁶ Four trials (total N = 391 children) met selection criteria (birth height or weight < 2 SDS, initial height < 2 SDS). The GH dose ranged from 33 to 67 μg/kg in the RCTs, and mean duration of treatment was 7.3 years. Mean adult height in the 4 studies was -1.5 SDS in the treated group and -2.4 SDS in the untreated group. Adult height in the treated group was significantly higher than that of controls (MD = 0.9 SDS [5.7 cm]; p < 0001). There was no difference in adult height between the 33 and 67 μg/kg/d doses. Reviewers noted that it is unclear whether the gain in adult height associated with GH treatment “is of sufficient clinical importance and value to warrant wide-spread treatment of short children born SGA [small for gestational age]….”

There are very few data on the psychosocial outcomes of short pediatric or adult stature related to intrauterine growth retardation and how these outcomes may be affected by GH therapy. As noted, data are inadequate to document that youths with short stature have either low self-esteem or a higher than average number of behavioral or emotional problems.

Section Summary: Small for Gestational Age Children
While a meta-analysis found that GH treatment resulted in significantly greater adult height in children born small for gestational age than a control treatment, the clinical implications of these findings has been called into question. Additionally, there are few data on psychological or functional outcomes associated with this additional gain in height.

ALTERED BODY HABITUS RELATED TO ANTIRETROVIRAL THERAPY FOR HIV INFECTION
Research has evaluated the use of GH for altered body habitus, which may be a complication of antiretroviral therapy for HIV infection. Body habitus changes, also referred to as fat redistribution syndrome or HIV-associated lipodystrophy syndrome, include thinning of the face, thinning of the extremities, truncal obesity, breast enlargement, or an increased dorsocervical fat pad (“buffalo hump”).⁵⁷ However, there is relatively little published literature on the use of GH for this indication, mostly letters to editors and small case series.

Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with altered body habitus related to antiretroviral therapy for HIV infection.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with altered body habitus due to antiretroviral therapy for HIV infection?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with altered body habitus related to antiretroviral therapy for HIV infection.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat altered body habitus due to antiretroviral therapy for HIV infection: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Treatment of 40 weeks is of interest to monitor outcomes.

Setting
Patients with HIV-related altered body habitus are actively managed by HIV specialists and infectious disease specialists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Randomized Controlled Trials
Because high-dose GH has been associated with adverse events relating to inflammation, Lindboe et al. (2016) conducted a randomized, double-blind, placebo-controlled trial to test the effect of low-dose GH in the treatment of HIV-infected patients on retroviral therapy.⁵⁸ Participants were randomized to GH 0.7 mg/day (n = 24) or placebo (n = 18) for 40 weeks. The primary outcome was change in inflammation measured by C-reactive protein and soluble urokinase plasminogen activator receptor (suPAR), both of which increase with inflammation. After 40 weeks, low-dose GH significantly lowered C-reactive protein. Low-dose GH lowered suPAR as well, but the difference was not statistically significant, even after controlling for age, weight, smoking status, and lipodystrophy.

Case Series
A large case series was reported by Wanke et al. (1999) who treated 10 HIV-infected patients with fat redistribution syndrome with GH for 3 months.⁵⁹ The authors reported improved waist/hip ratio and mid- thigh circumference.

Section Summary: Altered Body Habitus Related to Antiretroviral Therapy for HIV Infection
An RCT comparing low-dose GH with placebo showed that the treatment could reduce inflammation experienced by HIV-infected patients who had altered body habitus related to antiretroviral therapy. A case series has reported reductions in visceral abdominal fat. Additional studies reporting a wider range of outcomes are needed.

CHILDREN WITH IDIOPATHIC SHORT STATURE
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with idiopathic short stature.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with idiopathic short stature?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with idiopathic short stature (without documented GHD or underlying pathology).

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat idiopathic short stature: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up at 2 years is of interest to monitor outcomes.

Setting
Patients with idiopathic short stature are actively managed by endocrinologists and geneticists in an outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Impact on Adult Height
Systematic Reviews
Several meta-analyses have assessed the impact of GH on idiopathic short stature and adult height. More recently, Deodati and Cianfarani (2011) identified 3 RCTs and 7 non-RCTs.⁶⁰ Selection criteria for the systematic review included prepubertal children with initial short stature (> 2 SD below the mean) and peak GH response greater than 10 μg/L. In addition, participants could not have had previous GH therapy or comorbid conditions that could impair growth. Adult height was defined as a growth rate of less than 1.5 cm/year or bone age of 15 years in females and 16 years in males. The primary efficacy outcome was the difference between groups in adult height, measured as SDS. The investigators considered an MD in height of more than 0.9 SDS (»6 cm) to be a satisfactory response to GH therapy. Only 1 randomized trial was placebo-controlled, and that trial had a high dropout rate (40% in the treated group, 65% in the placebo group).

In the 3 RCTs (n = 115 patients), the mean adult height (primary efficacy outcome) was -1.52 SDS for treated children and -2.30 SDS for untreated children. The difference between groups significantly favored the treated group (MD = 0.65 SDS [»4 cm]; 95% CI, 0.40 to 0.91; p < 0.001). The mean adult height in the 7 nonrandomized studies was -1.7 SDS for treated children and -2.1 SDS for untreated children. The MD between groups was 0.45 SDS (3 cm) (95% CI, 0.18 to 0.73) and was statistically significant favoring the treated group (p < 0.001). Although GH treatment resulted in a statistically significant increase in adult height in the treated group, according to the a priori definition of a satisfactory response (difference, 0.9 SDS), the difference was not clinically significant. Moreover, there was a lack of high-quality, placebo-controlled randomized trials.

A Cochrane review by Bryant et al. (2007) evaluated GH therapy for idiopathic short stature in children and adolescents.⁶¹ Ten RCTs met eligibility criteria, which included studies conducted in children who had normal GH secretion, normal size for gestational age at birth, and no evidence of chronic organic disease. In addition, studies had to compare GH treatment with placebo or no treatment and provide GH treatment for at least 6 months. Three studies were placebo-controlled, and the other seven compared GH therapy with no treatment. Unlike the Deodati and Cianfarani review (previously described), studies were not required to report final adult height. Nine of 10 studies in the Cochrane review were short term and reported intermediate outcomes. A pooled analysis of 3 studies reporting growth velocity at 1 year found a statistically significant greater growth velocity in treated than in untreated children. The weighted mean difference was 2.84 (95% CI, 2.06 to 2.90). Five studies reported height SDSs, but there was heterogeneity among studies, and findings were not pooled. These data would suggest that GH has an effect on height in children with idiopathic short stature in the short term but that evidence on GH’s effects on adult height is extremely limited.

Impact on Self-Esteem and Quality of Life
Advocates of GH therapy often cite the potential psychosocial impairments associated with short stature. Several RCTs have investigated this issue and did not find better self-esteem, psychological functioning, or quality of life in children treated with GH compared with controls. These studies are briefly described next.

Randomized Controlled Trials
Ross et al. (2004) published findings on psychological adaptation in 68 children with idiopathic short stature without GHD.⁶² Children (mean age, 12.4 years) were randomized to GH therapy (n = 37) or placebo (n = 31) 3 times per week until height velocity decreased to less than 1.5 cm/y. At baseline and then yearly, parents and children completed several psychological instruments including the Child Behavior Checklist (CBCL) and the Self-Perception Profile. No significant associations were found between attained height SDS or change in height SDS and annual changes in CBCL scores. There were no significant differences between groups on any CBCL summary scales in years 1 and 2, but, in year 4, there were significantly higher scores on the CBCL summary scales in the group receiving GH treatment. There were no significant differences between groups on the Self-Perception Profile at any follow-up point. This trial did not find a correlation between short stature and psychological adaptation or self- concept.

Theunissen et al. (2002) in the Netherlands published a trial in which 40 prepubertal children with idiopathic short stature were randomized to GH treatment (n = 20) or a control group (n = 20).⁶³ Parents and children were interviewed at baseline and at 1 and 2 years to obtain information on health-related quality of life and children’s self-esteem. At the 2-year follow-up, satisfaction with current height was significantly associated with improvement in children’s reported health-related quality of life, social functioning, and other psychosocial measures. However, satisfaction with height did not differ significantly between the treatment and control groups. The data from this trial did not support the hypothesis that GH treatment improves health-related quality of life in children with idiopathic short stature.

Downie et al. (1996) examined the behavior of children without documented GHD who were treated with GH due to idiopathic short stature.⁶⁴ Across measures of behavior, including IQ, self-esteem, self- perception, or parental perceptions of competence, there were no significant differences between the control and the treatment groups, either at baseline or after 5 years of GH therapy. The authors concluded that while no psychosocial benefits of GH therapy have been demonstrated, likewise, no documented psychosocial ill effects of GH treatment have been demonstrated.

Section Summary: Children With Idiopathic Short Stature
Systematic reviews have found that GH treatment may increase height gain for children with idiopathic short stature, but the difference in height gain may not be clinically significant. The absolute difference in height in these studies ranged from 3 to 4 cm; further, children treated with GH remained below average in height, with heights between 1 and 2 SD below the mean at the end of treatment (note: these studies did not follow treated patients long enough to determine the ultimate impact of GH on final adult height).

RCTs have not found that short stature is associated with psychological problems, contrary to the expectations of some advocates. In addition, the available trials have not reported a correlation between increases in height and improvements in psychological functioning. Moreover, this group of children is otherwise healthy, and there are potential risks to GH therapy in childhood (see previous section Safety of Growth Hormone Treatment).

CHILDREN WITH “GENETIC POTENTIAL”
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with “genetic potential”.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with “genetic potential”?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with “genetic potential.”

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat children with “genetic potential”: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Due to the lack of relevant data, it is not possible to determine an appropriate window for follow-up.

Setting
Patients with “genetic potential” are actively managed by endocrinologists and geneticists in an outpatient clinical setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Clinical Studies
No randomized or nonrandomized studies were identified that have evaluated the efficacy, safety, and/or psychosocial impacts of treating children with “genetic potential” (i.e., children with lower than expected high percentiles based on their parents’ height).

Section Summary: Children With “Genetic Potential”
There is insufficient evidence to draw conclusions about the use of human GH to treat “genetic potential.”

PRECOCIOUS PUBERTY
Precocious puberty is generally defined as the onset of secondary sexual characteristics before eight years of age in girls and 9 years in boys. Central precocious puberty is related to hypothalamic pituitary gonadal activation, leading to increase in sex steroid secretion, which accelerates growth and causes premature fusion of epiphyseal growth plates, thus impacting final height. Children with precocious puberty are often treated with gonadotropin-releasing hormone (GnRH) analogues to suppress the pituitary gonadal activity, to slow the advancement of bone age, and to improve adult height.

Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with precocious puberty.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in children with precocious puberty?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is children with precocious puberty.

Interventions
The therapy being considered is human GH plus GnRH

Comparators
The following practice is currently being used to treat precocious puberty: GnRH only.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Follow-up at 2 years is of interest to monitor outcomes.

Setting
Patients with precocious puberty are actively managed by endocrinologists in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
Liu et al. (2016) published a meta-analysis comparing GnRH with the combination therapy of GH plus GnRH for the treatment of females who had idiopathic central precocious puberty.⁶⁵ The literature search, conducted through December 2014, identified 6 RCTs (n = 162) and 6 clinical controlled trials (n = 247) for inclusion. Risk of bias in the RCTs was assessed using the Cochrane Collaboration checklist. Five of the RCTs were determined to have moderate risk of bias and 1 trial had a high risk of bias. The controlled trials were assessed using the Methodological Index for Nonrandomized Studies (MINORS), based on 12 items, with an ideal global score of 24. Scores on MINORS for the 6 controlled trials ranged from 17 to 20, because none of the trials reported blinded outcome evaluation or prospective calculation of study size. Primary outcomes included final height, difference between final height and targeted height, and height gain. Among the 12 included studies, age of participants ranged from 4.6 to 12.2 years and treatment with the combination therapy ranged from 6 months to 3 years. One RCT and 4 controlled trials provided data for the meta-analyses. Results showed that patients receiving the combination therapy for at least 1 year experienced significantly greater final height, difference in final height and targeted height, and height gain compared with those receiving GnRH alone (MD = 2.8 cm [95% CI, 1.8 to 3.9 cm]; MD = 3.9 cm [95% CI, 3.1 to 4.7 cm]; MD = 3.5 cm [95% CI, 1.0 to 6.0 cm], respectively). When treatment duration was less than 1 year, no significant differences in the height outcomes were found.

Randomized Controlled Trials
One RCT compared GnRH analogues alone with GnRH analogues plus GH therapy. This trial, by Tuvemo et al. (1999), included 46 girls with precocious puberty.⁶⁶ Criteria for participation did not include predicted adult height or growth velocity. After 2 years of treatment, mean growth and predicted adult height were greater in those receiving combined treatment than in those receiving GnRH analogues alone. The absence of final height data limited interpretation of this trial.

Case Series
A case series by Pucarelli et al. (2003) reported on 17 girls with precocious puberty and a growth velocity below the 25th percentile who were treated with a combination of GnRH and GH, and 18 girls who refused treatment with adjunctive GH.⁶⁷ Those in the combined group attained a significantly greater adult height (161.2 cm) than the “control” group (156.7 cm).

Section Summary: Precocious Puberty
Evidence for the incremental benefit of GH added to GnRH therapy in patients with precocious puberty consists of a systematic review, an RCT, and case series. One RCT and 4 controlled trials of moderate quality provided data for the meta-analyses. Small, but statistically significant differences were reported in final height (2.8 cm), in the difference between final height and targeted height (3.9 cm), and in height gain (3.5 cm) for patients who received the combination therapy for at least one year compared with patients receiving GnRH alone. Interpretation of results from the RCT and small comparative case series not included in the systematic review is limited because of methodologic issues. No studies have reported on the impact of short stature on functional or psychological outcomes.

OLDER ADULTS WITH AGE-RELATED GHD
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients who are older adults with age-related GHD.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in older adults with age-related GHD?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is older adults with age-related GHD.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat older adults with age-related GHD: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Due to the lack of relevant data, it is not possible to determine the window for follow-up.

Setting
Older adults with age-related GHD are actively managed by endocrinologists and primary care physicians in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
A TEC Assessment (2001) investigated the use of GH in older adults with age-related GHD and concluded that there was insufficient evidence of efficacy.⁶⁸ It is not possible to prove effectiveness of GH treatment or lack thereof unless otherwise similar groups of treated vs nontreated patients are compared over a sufficient length of time to allow detection of any significantly and clinically different results.

Section Summary: Older Adults With Age-Related GHD
A TEC Assessment concluded that there is a lack of evidence that GH therapy in older adults improves health outcomes. No subsequent controlled studies were identified.

CYSTIC FIBROSIS
Clinical Context and Test Purpose
The purpose of human GH is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients with cystic fibrosis.

The question addressed in this evidence review is: Does use of human GH improve the net health outcome in individuals with cystic fibrosis?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is individuals with cystic fibrosis.

Interventions
The therapy being considered is human GH.

Comparators
The following practice is currently being used to treat cystic fibrosis: standard care without human GH treatment.

Outcomes
The general outcomes of interest are functional outcomes, quality of life, and treatment-related morbidity.

Timing
Treatment of 1 year is of interest to monitor outcomes.

Setting
Patients with cystic fibrosis are actively managed by endocrinologists, pulmonologists, and physical therapist in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the principles outlined in indication 1.

Systematic Reviews
A Cochrane review by Thaker et al. (2013) evaluated GH therapy for improving lung function, nutritional status, and quality of life in children and young adults with cystic fibrosis.⁶⁹ Reviewers identified 4 RCTs (total N = 161 participants). All studies used daily subcutaneous injection of human GH as the intervention and included a no treatment or placebo control group. All trials measured pulmonary function and nutritional status. Due to differences in how outcomes were measured, study findings were not pooled. Across trials, GH improved intermediate outcomes such as height and weight; however, improvements in lung function were inconsistent. No significant changes in quality of life or clinical status were detected.

Previously, a systematic review by Phung et al. (2010) identified 10 controlled trials evaluating GH for treating patients with cystic fibrosis.⁷⁰ One study was placebo-controlled, eight compared GH therapy with no treatment, and the remaining trial compared GH alone with glutamine or glutamine plus GH. Treatment durations ranged from 4 weeks to 1 year. There were insufficient data to determine the effect of GH on most health outcomes (e.g., frequency of intravenous antibiotic treatment, quality of life, bone fracture). Data were pooled for a single outcome, frequency of hospitalizations. In trials lasting at least 1 year, there were significantly lower rates of hospitalizations per year in groups receiving GH therapy (pooled effect size, - 1.62; 95% CI, -1.98 to -1.26).

Randomized Controlled Trials
An industry-sponsored, open-label RCT was published by Stalvey et al. (2012).⁷¹ It compared GH therapy with no treatment in prepubertal children with cystic fibrosis younger than 14 years old. Eligibility criteria included height less than the 10th percentile for age and sex; children with documented GHD were excluded. Participants were treated daily for 12 months and followed for another 6 months. The trial included 68 children; 62 (91%) were included in the efficacy analysis, and all but one were included in the safety analysis. The annualized height velocity at month 12 was 8.2 cm/y in the treatment group and 5.3 cm/y in the control group (p < 0.001). The mean height SDS in the treatment group was -1.8 at baseline, -1.4 at 12 months, and -1.4 at 18 months vs -1.9 at all 3 time points in the control group. The change in mean height SDS from baseline to 12 months was significantly greater in the treatment than in the control group (p < 0.001). Between months 12 and 18, the control group remained at the same height SDS, while the treatment group experienced a slight decline (0.1 SDS), but maintained a 0.5 SDS advantage over the control group.

In terms of pulmonary outcomes, the unadjusted rate of change from baseline to 12 months for most variables (7 of 8 pulmonary test results) did not differ between groups. However, the unadjusted change from 12 to 18 months (after treatment ended) was significantly greater in the control group than in the treatment group for 4 of 7 pulmonary test variables, including forced expiratory volume in 1 second (FEV1) (p < 0.005) and forced vital capacity (p < 0.01). In the treatment group, mean FEV1 was 1209 liters at baseline, 1434 liters at 12 months, and 1467 liters at 18 months compared with 1400 liters at baseline, 1542 liters at 12 months, and 1674 liters at 18 months in the control group. From baseline to 12 months, the between-group difference in change in the 6-minute walk distance did not differ significantly (26.3 meters; 95% CI, -44.8 to 97.4 meters). Ten children in the treatment group and nine in the control group were hospitalized for pulmonary exacerbations during the 12-month trial; the difference between groups was not statistically significant. In general, treatment with GH resulted in statistically significant improvements in height SDS but did not significantly improve clinical outcomes associated with cystic fibrosis.

Section Summary: Cystic Fibrosis
Several RCTs and systematic reviews have been identified. The RCTs were heterogenous and reported a variety of outcomes. None of the systematic reviews pooled results for outcomes (e.g., frequency of intravenous antibiotic treatment, quality of life, bone fracture). The single pooled outcome (number of hospitalizations) was significantly lower in patients receiving GH therapy vs no treatment or placebo.

Across the trials, GH improved intermediate outcomes such as height and weight; however, clinically meaningful outcomes relating to lung function did not consistently improve with GH.

SUMMARY OF EVIDENCE
For individuals who have proven GHD who receive human GH, the evidence includes RCTs, large observational studies, and meta-analyses. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Studies have found that, for patients with documented GHD and clinical manifestations such as short stature, GH replacement improves growth velocity and final height achieved. In addition, studies have shown that GH therapy can ameliorate the secondary manifestations of GHD such as increase in lean muscle mass and bone mineral density seen primarily in older children and adults. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to Noonan syndrome who receive human GH, the evidence includes a systematic review of controlled and uncontrolled studies. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. While the studies in the systematic review were generally of low quality and included only 1 trial comparing patients receiving GH with patients receiving no treatment, reviewers found that GH therapy was associated with an increase in height in patients with Noonan syndrome. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short stature due to SHOX deficiency who receive human GH, the evidence includes an RCT and a long-term observational study. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The RCT found that children with short stature due to SHOX deficiency had significantly greater height velocity and height gain after 2 years when treated with GH than with no GH. The long-term study reported that, after 4 to 6 years of GH treatment, patients with SHOX deficiency may attain near-adult height. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AIDS wasting who receive human GH, the evidence includes observational studies, RCTs, and a systematic review. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. A systematic review with meta-analysis found significant improvements in lean body mass with GH therapy vs placebo; several studies found improvements in quality of life. An RCT with a large sample size reported a significantly greater increase in exercise capacity with GH than with placebo. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have short bowel syndrome on specialized nutritional support who receive human GH, the evidence includes RCTs and a meta-analysis. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. A pooled analysis of 3 small trials found significantly greater weight gain with GH therapy than with placebo, and other studies found improved intestinal absorption in patients with short bowel syndrome receiving parenteral nutrition. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are small for gestational age in childhood who receive human GH, the evidence includes RCTs and a meta-analysis. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The meta-analysis found that GH treatment in small for gestational age children resulted in significantly greater adult height compared with no treatment; however, the clinical significance of the height difference between the study groups is unclear. There are few data on the psychological or functional outcomes associated with this additional gain in height. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have altered body habitus related to antiretroviral therapy for HIV infection who receive human GH, the evidence includes an RCT and case series. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The RCT measured the effect of low-dose GH on intermediate outcomes (inflammation markers). Case series data are insufficient for drawing conclusions about the impact of GH treatment on health outcomes in HIV-infected patients with altered body habitus due to antiretroviral therapy. Controlled studies reporting relevant outcomes are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have idiopathic short stature who receive human GH, the evidence includes RCTs and systematic reviews. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Systematic reviews have found that GH treatment may increase height gain for children with idiopathic short stature, but the difference in height gain may not be clinically significant. The available studies did not follow treated patients long enough to determine the ultimate impact of GH on final adult height. RCTs have not found that short stature is associated with psychological problems, contrary to the expectations of some advocates. In addition, the available trials have not reported a correlation between increases in height and improvements in psychological functioning. Moreover, this group of children is otherwise healthy, and there are potential risks to GH therapy in childhood. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have “genetic potential” (i.e., lower than expected height percentiles based on parents’ height) who receive human GH, the evidence includes no clinical trials. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. No published literature was identified on GH therapy as a treatment of children with “genetic potential.” The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have precocious puberty who receive human GH plus gonadotropin-releasing hormone, the evidence includes a systematic review, an RCT, and a comparative case series. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. While the systematic review included RCTs and controlled trials, only 1 RCT and 4 controlled trials provided data for the meta- analyses of final height, difference in final height and targeted height, and height gain. The meta-analyses reported statistically significant gains of several centimeters for patients who received the combination therapy for at least 1 year compared with patients receiving gonadotropin-releasing hormone alone. However, no studies have reported on the impact of short stature on functional or psychological outcomes in this population. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are older adults with age-related GHD who receive human GH, the evidence includes a systematic review (TEC Assessment). Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The TEC Assessment concluded there is a lack of evidence that GH therapy in older adults improves health outcomes. No subsequent controlled studies were identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have cystic fibrosis who receive human GH, the evidence includes RCTs and systematic reviews. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. The RCTs were heterogenous and reported various outcomes. None of the systematic reviews pooled results for outcomes such as frequency of intravenous antibiotic treatment, quality of life, and bone fracture. The single pooled outcome (number of hospitalizations) was significantly lower in patients receiving GH therapy vs no treatment or placebo. Across trials, GH was found to improve intermediate outcomes such as height and weight; however, clinically meaningful outcomes relating to lung function were not consistently improved with GH. The evidence is insufficient to determine the effects of the technology on health outcomes.

PRACTICE GUIDELINES AND POSITION STATEMENTS
Pediatric Endocrine Society
In 2015, the Pediatric Endocrine Society (PES) published an evidence-based report focusing on the risk of neoplasia in patients receiving growth hormone (GH) therapy.⁷² The report concluded that GH therapy can be administered without concerns about impact on neoplasia in children without known risk factors for malignancy. For children with medical conditions associated with an increased risk of future malignancies, patients should be evaluated on an individual basis and decisions made about the tradeoff between a possible benefit of GH therapy and possible risks of neoplasm.

As an addendum to the 2015 guidelines, Grimberg and Allen (2017), guidelines coauthors, published a historical review of the use of GH.⁷³ They asserted that although the guidelines did not find an association between GH and neoplasia, the use of GH should not necessarily be expanded. While the use of GH for patients with growth hormone deficiency (GHD) was recommended, evidence gaps persist in the use of GH for other indications such as idiopathic short stature and partial isolated GHD.

In 2016, the PES published guidelines for GH and insulin-like growth factor 1 treatment for children and adolescents with GHD, idiopathic short stature, and primary insulin-like growth factor-I deficiency.⁷⁴ The guidelines used the GRADE approach (grading of recommendations, assessment, development, and evaluation). The following recommendations were made:

“We recommend the use of GH to normalize adult height and avoid extreme shortness in children and adolescents with GHD. (strong recommendation, high quality evidence)
“We suggest a shared decision-making approach to pursuing GH treatment for a child with idiopathic short stature. The decision can be made on a case by case basis after assessment of physical and psychological burdens, and discussion of risks and benefits. We recommend against the routine use of GH in every child with height SDS [standard deviation score] ≤ -2.25. (conditional recommendation, moderate quality evidence)

In 2017, PES published practice guidelines on the management of Turner syndrome based on proceedings of the International Turner Syndrome Meeting.⁷⁵ PES recommended initiating GH treatment early, around 4 to 6 years of age, and preferably before 12 to 13 years if the child had evidence of growth failure ( < 50th percentile height velocity) or had a strong likelihood of short stature (moderate quality of evidence).

Endocrine Society
Endocrine Society practice guidelines on adult GHD, updated in 2011, included the following recommendation⁷⁶:

GH therapy for GHD adults offers significant clinical benefits in body composition and exercise capacity.
GH therapy for GHD adults offers significant clinical benefits in skeletal integrity.
After documentation of persistent GHD, GH therapy should be continued after completion of adult height to obtain full skeletal/muscle maturation during the transition period.

National Institute of Health and Care Excellence
In 2010, the National Institute of Health and Care Excellence issued guidance on human GH for growth failure in children.⁷⁷ The Institute recommended GH as a possible treatment for children with growth failure with any of the following conditions:

GHD
Turner syndrome
Prader-Willi syndrome
Chronic renal insufficiency
Small for gestational age and have growth failure at 4 years
Short stature homeobox-containing gene (SHOX) deficiency.

American Association of Clinical Endocrinologists
In 2009, the American Association of Clinical Endocrinologists updated its guidelines on GH use in GHD adults and transition patients.⁷⁸ Evidence-based recommendations included the following:

GHD is a well-recognized clinical syndrome in adults that is associated with significant comorbidities if untreated
GH should only be prescribed to patients with clinical features suggestive of adult GHD and biochemically proven evidence of adult GHD
No data are available to suggest that GH has beneficial effects in treating aging and age-related conditions and the enhancement of sporting performance; therefore, GH treatment was not recommended for any reason other than the well-defined approved uses of the drug.

Growth Hormone Research Society et al.
In 2008, the Growth Hormone Research Society (GHRS), Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop published a consensus statement on the diagnosis and treatment of children with idiopathic short stature.⁷⁹ The statement indicated that the appropriate height below which GH treatment should be considered ranged from -2 to -3 standard deviation score. The optimal age for treatment was thought to be between 5 years and early puberty. The group noted that psychological issues should be considered (eg, GH therapy should not be recommended for short children who are unconcerned about stature). The statement also mentioned that “psychological counseling is worthwhile to consider instead of or as an adjunct to hormone treatment.”

In 2013, GHRS issued consensus guidelines on human GH therapy for Prader-Willi syndrome (PWS).⁸⁰ The following recommendations were made:

“After genetic confirmation of the diagnosis of PWS, rhGH [recombinant human growth hormone] treatment should be considered and, if initiated, should be continued for as long as demonstrated benefits outweigh the risks.”
“GH stimulation testing should not be required as part of the therapeutic decision-making process in infants and children with PWS.”
“Exclusion criteria for starting rhGH in patients with PWS include severe obesity, uncontrolled diabetes, untreated severe obstructive sleep apnea, active cancer, and active psychosis.”
Scoliosis and cognitive impairment should not be considered exclusion criteria.

In 2016, results from the Growth Hormone Safety Workshop were published in the European Journal of Endocrinology.⁸¹ The workshop was convened by GHRS and other medical societies. The workshop reappraised the safety of human GH. The position statement concluded:

After following children and adults for tens of thousands of person-years, the safety profile of rhGH remains good when rhGH is used for approved indications and at recommended doses. There is no evidence supporting an association between rhGH and overall mortality, risk of new primary cancer, risk of recurrence of primary cancer, risk of stroke, or risk of cardiovascular disease.
A carefully designed cohort study, providing continued long-term surveillance of patients treated with rhGH, would address the current limitations of safety data (eg, inconsistent definitions of outcomes, low incidence outcomes, and lack of dose-specific assessments).

American Academy of Pediatrics
In 2016, the American Academy of Pediatrics published guidelines on the evaluation and referral of children with signs of early puberty.⁸² The use of gonadotropin-releasing hormone analogues were discussed as treatment options, but GH as a treatment option was not discussed.

U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS
Not applicable

ONGOING AND UNPUBLISHED CLINICAL TRIALS
Currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing
NCT03245333^a	Phase III Clinical Study of Recombinant Human Growth Hormone Injection (JINTOPIN AQ) for Short Children with Small for Gestational Age (SGA)	120	Dec 2017 (ongoing)
NCT02770157^a	Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age	75	Jun 2019
NCT03038594	Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients	62	Oct 2019
NCT01196156^a	An Observational Phase IV Study for Prospective Follow-Up to Adult Height of a Cohort of Subjects Born Small for Gestational Age and Treated with Growth Hormone	443	Feb 2020
NCT00537914^a	Long-term Phase IV Multicenter Study on the Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)	278	Mar 2021
NCT03535415a	A Phase 3 Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation	68	Dec 2021
NCT01604395^a	An Open, Multi-Center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj./Eutropin plus Inj.) Treatment with GHD, TS, CRF, SGA, and ISS in Children	2,000	Jan 2022
Unpublished
NCT01246219^a	The Influence of Growth Hormone (GH) Therapy on Short Stature Related Distress a Prospective Randomized Controlled Trial	60	Nov 2017 (completed)
NCT01897766^a	Special Investigation for Genotropin (SGA Long-term Follow-up)	488	Feb 2017 (completed)
NCT01248416^a	A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature	76	Sep 2016 (completed)
NCT01746862^a	A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-Controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen® 0.067 mg/kg/Day subcutaneous Injection in Children with Idiopathic Short Stature	90	Mar 2015 (completed)

NCT: national clinical trial.
ª Denotes industry-sponsored or cosponsored trial.

References

Strasburger CJ, Vanuga P, Payer J, et al. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol. Mar 2017;176(3):283-294. PMID 27932411
Luo X, Hou L, Liang L, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. Aug 2017;177(2):195-205. PMID 28566441
Hoybye C, Pfeiffer AF, Ferone D, et al. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. Endocr Connect. Apr 2017;6(3):129-138. PMID 28196799
Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab. May 1996;81(5):1704-1710. PMID 8626820
Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab. May 2001;86(5):1868-1870. PMID 11344173
Swerdlow AJ, Cooke R, Beckers D, et al. Cancer risks in patients treated with growth hormone in childhood: The SAGhE European Cohort Study. J Clin Endocrinol Metab. May 01 2017;102(5):1661-1672. PMID 28187225
Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. Feb 2012;97(2):416-425. PMID 22238382
Poidvin A, Touze E, Ecosse E, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. Aug 26 2014;83(9):780-786. PMID 25122206
Pfizer. Highlights of Prescribing Information: Genotropin (somatropin [rDNA origin] for injection). 2014; https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020280s078lbl.pdf. Accessed September 29, 2018.
Eli Lilly. Highlights of Prescribing Information: Humatrope (somatropin [rDNA ORIGIN] for injection, for Subcutaneous Use). 2016; http://pi.lilly.com/us/humatrope-pi.pdf. Accessed September 29, 2018.
Root AW, Kemp SF, Rundle AC, et al. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994. J Pediatr Endocrinol Metab. Aug 1998;11(3):403-412. PMID 11517956
Reiter EO, Price DA, Wilton P, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab. Jun 2006;91(6):2047-2054. PMID 16537676
Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. Jun 2008;93(6):2063-2071. PMID 18381581
Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. Nov 2008;93(11):4413-4417. PMID 18697875
Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin Endocrinol (Oxf). Jun 2010;72(6):787-792. PMID 19769614
Xue P, Wang Y, Yang J, et al. Effects of growth hormone replacement therapy on bone mineral density in growth hormone deficient adults: a meta-analysis. Int J Endocrinol. May 2013;2013:216107. PMID 23690770
Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. Mar 2014;99(3):852- 860. PMID 24423364
Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. May 2004;89(5):2048-2056. PMID 15126520
Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta- analysis. Circulation. Nov 25 2003;108(21):2648-2652. PMID 14623813
Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. Jul 18 2000;133(2):111-122. PMID 10896637
Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH- deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab. Oct 2001;86(10):4657-4665. PMID 11600522
Ishii H, Shimatsu A, Nishinaga H, et al. Assessment of quality of life on 4-year growth hormone therapy in Japanese patients with adult growth hormone deficiency: A post-marketing, multicenter, observational study. Growth Horm IGF Res. Oct 2017;36:36-43. PMID 28923784
Kuppens RJ, Bakker NE, Siemensma EP, et al. Beneficial effects of GH in young adults With Prader-Willi syndrome: a 2-year crossover trial. J Clin Endocrinol Metab. Nov 2016;101(11):4110-4116. PMID 27552545
Lo ST, Siemensma EP, Festen DA, et al. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study. Eur Child Adolesc Psychiatry. Sep 2015;24(9):1091-1101. PMID 25522840
Reus L, Pelzer BJ, Otten BJ, et al. Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial. Res Dev Disabil. Oct 2013;34(10):3092-3103. PMID 23886754
Festen DA, de Lind van Wijngaarden R, van Eekelen M, et al. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxf). Sep 2008;69(3):443-451. PMID 18363884
Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. Jul 2012;97(7):2307-2314. PMID 22508707
Craig ME, Cowell CT, Larsson P, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf). Aug 2006;65(2):178-185. PMID 16886957
Van Vliet G, Deal CL, Crock PA, et al. Sudden death in growth hormone-treated children with Prader-Willi syndrome. J Pediatr. Jan 2004;144(1):129-131. PMID 14722532
Grugni G, Livieri C, Corrias A, et al. Death during GH therapy in children with Prader-Willi syndrome: description of two new cases. J Endocrinol Invest. Jun 2005;28(6):554-557. PMID 16117198
Wu Y, Cheng W, Yang XD, et al. Growth hormone improves growth in pediatric renal transplant recipients--a systemic review and meta-analysis of randomized controlled trials. Pediatr Nephrol. Jan 2013;28(1):129-133. PMID 22660958
Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. Feb 15 2012;2(2):CD003264. PMID 22336787
Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, et al. Placebo-controlled, double-blind, cross- over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet. Sep 7 1991;338(8767):585-590. PMID 1715501
Hokken-Koelega A, Mulder P, De Jong R, et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol. Jul 2000;14(7):701-706. PMID 10912546
Bizzarri C, Lonero A, Delvecchio M, et al. Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration. J Endocrinol Invest. Mar 2018;41(3):325-331. PMID 28819753
Li P, Cheng F, Xiu L. Height outcome of the recombinant human growth hormone treatment in Turner syndrome: a meta-analysis. Endocr Connect. Apr 2018;7(4):573-583. PMID 29581156
Baxter L, Bryant J, Cave CB, et al. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev. Jan 24 2007(1):CD003887. PMID 17253498
Juloski J, Dumancic J, Scepan I, et al. Growth hormone positive effects on craniofacial complex in Turner syndrome. Arch Oral Biol. Nov 2016;71:10-15. PMID 27372203
Giacomozzi C, Deodati A, Shaikh MG, et al. The impact of growth hormone therapy on adult height in noonan syndrome: a systematic review. Horm Res Paediatr. Feb 2015;83(3):167-176. PMID 25721697
MacFarlane CE, Brown DC, Johnston LB, et al. Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up. J Clin Endocrinol Metab. May 2001;86(5):1953-1956. PMID 11344190
Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. Sep 2010;14(42):1-209, iii-iv. PMID 20849734
Blum WF, Crowe BJ, Quigley CA, et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. Jan 2007;92(1):219-228. PMID 17047016
Benabbad I, Rosilio M, Child CJ, et al. Safety outcomes and near-adult height gain of growth hormone-treated children with SHOX deficiency: data from an observational study and a clinical trial. Horm Res Paediatr. Dec 2017;87(1):42-50. PMID 28002818
Breederveld RS, Tuinebreijer WE. Recombinant human growth hormone for treating burns and donor sites. Cochrane Database Syst Rev. Dec 12 2012;12:CD008990. PMID 23235668
Knox J, Demling R, Wilmore D, et al. Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma. Sep 1995;39(3):526-530; discussion 530-522. PMID 7473919
Singh KP, Prasad R, Chari PS, et al. Effect of growth hormone therapy in burn patients on conservative treatment. Burns. Dec 1998;24(8):733-738. PMID 9915674
Losada F, Garcia-Luna PP, Gomez-Cia T, et al. Effects of human recombinant growth hormone on donor-site healing in burned adults. World J Surg. Jan 2002;26(1):2-8. PMID 11898025
Hart DW, Herndon DN, Klein G, et al. Attenuation of posttraumatic muscle catabolism and osteopenia by long- term growth hormone therapy. Ann Surg. Jun 2001;233(6):827-834. PMID 11371741
Aili Low JF, Barrow RE, Mittendorfer B, et al. The effect of short-term growth hormone treatment on growth and energy expenditure in burned children. Burns. Aug 2001;27(5):447-452. PMID 11451596
Moyle GJ, Schoelles K, Fahrbach K, et al. Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. Dec 1 2004;37(Suppl 5):S262-276. PMID 15722869
Evans WJ, Kotler DP, Staszewski S, et al. Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read. Jun 2005;15(6):301-303, 306-308, 310, 314. PMID 15962453
Wales PW, Nasr A, de Silva N, et al. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev. Jun 16 2010(6):CD006321. PMID 20556765
Scolapio JS. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. JPEN J Parenter Enteral Nutr. Nov-Dec 1999;23(6):309-312; discussion 312-303. PMID 10574477
Seguy D, Vahedi K, Kapel N, et al. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology. Feb 2003;124(2):293-302. PMID 12557135
Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut. Aug 2000;47(2):199-205. PMID 10896910
Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics. Sep 2009;124(3):e519-531. PMID 19706577
Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet. Mar 21 1998;351(9106):867-870. PMID 9525364
Lindboe JB, Langkilde A, Eugen-Olsen J, et al. Low-dose growth hormone therapy reduces inflammation in HIV- infected patients: a randomized placebo-controlled study. Infect Dis (Lond). Nov-Dec 2016;48(11-12):829-837. PMID 27417288
Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. Oct 22 1999;13(15):2099-2103. PMID 10546863
Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. Mar 11 2011;342:c7157. PMID 21398350
Bryant J, Baxter L, Cave CB, et al. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev. Jul 18 2007(3):CD004440. PMID 17636758
Ross JL, Sandberg DE, Rose SR, et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab. Oct 2004;89(10):4873-4878. PMID 15472178
Theunissen NC, Kamp GA, Koopman HM, et al. Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr. May 2002;140(5):507-515. PMID 12032514
Downie AB, Mulligan J, McCaughey ES, et al. Psychological response to growth hormone treatment in short normal children. Arch Dis Child. Jul 1996;75(1):32-35. PMID 8813867
Liu S, Liu Q, Cheng X, et al. Effects and safety of combination therapy with gonadotropin-releasing hormone analogue and growth hormone in girls with idiopathic central precocious puberty: a meta-analysis. J Endocrinol Invest. Oct 2016;39(10):1167-1178. PMID 27225286
Tuvemo T, Gustafsson J, Proos LA. Growth hormone treatment during suppression of early puberty in adopted girls. Swedish Growth Hormone Advisory Group. Acta Paediatr. Sep 1999;88(9):928-932. PMID 10519330
Pucarelli I, Segni M, Ortore M, et al. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab. Sep 2003;16(7):1005-1010. PMID 14513877
Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Recombinent Human Growth Hormone (GH) Therapy in Adults with Age-Related GH Deficiency. TEC Assessment. 2001;Tab 11. PMID
Thaker V, Haagensen AL, Carter B, et al. Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database Syst Rev. Jun 05 2013;6(6):CD008901. PMID 23737090
Phung OJ, Coleman CI, Baker EL, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics. Nov 2010;126(5):e1211-1226. PMID 20921071
Stalvey MS, Anbar RD, Konstan MW, et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol. Mar 2012;47(3):252-263. PMID 21905270
Raman S, Grimberg A, Waguespack SG, et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab. Jun 2015;100(6):2192-2203. PMID 25839904
Grimberg A, Allen DB. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr Opin Pediatr. Aug 2017;29(4):466-471. PMID 28525404
Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin- like growth factor-I deficiency. Horm Res Paediatr. Nov 2016;86(6):361-397. PMID 27884013
Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. Sep 2017;177(3):G1-G70. PMID 28705803
Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Jun 2011;96(6):1587-1609. PMID 21602453
National Institute for Health and Care Excellence (NICE). Human growth hormone (somatropin) for growth failure in children [TA188]. 2010; https://www.nice.org.uk/guidance/ta188. Accessed September 29, 2018.
Cook DM, Yuen KC, Biller BM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. Sep-Oct 2009;15(Suppl 2):1-29. PMID 20228036
Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. Nov 2008;93(11):4210-4217. PMID 18782877
Deal CL, Tony M, Hoybye C, et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. Jun 2013;98(6):E1072-1087. PMID 23543664
Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. Feb 2016;174(2):P1-9. PMID 26563978
Kaplowitz P, Bloch C, Section on Endocrinology American Academy of Pediatrics. Evaluation and referral of children with signs of early puberty. Pediatrics. Jan 2016;137(1). PMID 26668298

Coding Section

Codes	Number	Description
CPT	96372	Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
ICD-9 Procedure	99.24	Injection of other hormone
ICD-9 Diagnosis	042	Human immunodeficiency virus
	253.2	Pituitary hormone deficiency (anterior)
	253.3	Pituitary dwarfism (includes isolated growth hormone deficiency)
	253.5	Pituitary hormone deficiency (posterior)
	259.1	Precocious sexual development and puberty
	579.3	Short bowel syndrome
	585.9	Chronic renal insufficiency
	756.89	Other specified anomalies of muscle, tendon, fascia or connective tissue (includes SHOX deficiency with dyschondrosteosis)
	758.6	Turner’s syndrome (includes SHOX deficiency with Turner’s syndrome)
	759.81	Prader-Willi syndrome
	764.90-764.99	Fetal growth retardation, unspecified (i.e., small for gestational age) code range
	783.40	Lack of normal physiological development, unspecified
	783.43	Short stature (includes SHOX deficiency with idiopathic short stature)
	799.4	Cachexia
	941.30 – 941.39	Burn of face, head, neck, full-thickness skin loss (third-degree burn not otherwise specified) code range
	943.30 – 943.39	Burn of upper limb, except wrist and hands, full-thickness skin loss (third-degree burn not otherwise specified) code range
	944.30 – 944.38	Burn of wrist(s) and hand(s) full-thickness skin loss (third-degree burn not otherwise specified) code range
	945.30 – 945.39	Burn of lower limb(s); full-thickness skin loss (third-degree burn not otherwise specified) code range
	946.3	Burns of multiple specified sites; full-thickness skin loss (third-degree not otherwise specified)
	949.3	Burn, unspecified; full-thickness skin loss
HCPCS	J2941	Injection, somatropin, 1 mg
	J3490	Unclassified drug
	S9558	Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, coordination of care, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
ICD-10-CM (effective 10/1/15)	E23.0 – E23.7	Hypofunction and other disorders of the pituitary gland; code range
	E30.1	Precocious puberty
	K91.2	Postsurgical malabsorption, not elsewhere classified (short bowel syndrome)
	N28.9	Disorder of kidney and ureter, unspecified
	P05.00 – P05.9	Disorders of newborn related to slow fetal growth and fetal malnutrition; code range
	Q96.0 – Q96.9	Turner’s syndrome; code range
	R62.0 – R62.59	Lack of expected normal physiological development in childhood and adults; code range
	B20	Human Immunodeficiency virus
	R64	Cachexia
	Q87.1	Prader-Willi syndrome
	T20.30xA- – T20.39xS	Burn of third degree of head, face and neck; code range
	T22.30xA - T22.39xS	Burn of third degree of shoulder and upper limb, except wrist and hand; code range
	T23.301A - T23.399S	Burn of third degree of wrist and hand; code range
	T24.301A- - T24.399S	Burn of third degree of lower limb, except ankle and foot; code range
	T25.311A - T25.399S	Burn of third degree of ankle and foot; code range
	T30.0	Burn of unspecified body region, unspecified degree
ICD-10-PCS (effective 10/1/15)		ICD-10-PCS codes are only used for inpatient services. There are no ICD-10-PCS codes for drugs.
	3E013VJ, 3E033VJ, 3E043VJ, 3E053VJ, 3E063VJ	Administration, introduction, other hormone, percutaneous, code by body part (subcutaneous tissue, peripheral vein, central vein, peripheral artery, or central artery)
Type of Service	Prescription Drug
Place of Service	Outpatient Physician’s Office

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies and accredited national guidelines.

History From 2014 Forward

11/16/2023	Annual review, no change to policy intent.
11/21/2022	Annual review, extensive additions to individual coverage criteria to provide guidelines for each covered condition.
11/16/2021	Annual review, no change to policy intent.
11/16/2020	Annual review, no change to policy intent.
11/06/2019	Annual review, no change to policy intent.
12/06/2018	Annual review, no change to policy intent. Updating rationale and references.
11/02/2017	Annual review, limited update to policy verbiage to indicate that for #6 in the medically necessary statement "children with growth failure due to Prader-Willi syndrome, who do not have the following contraindications: history of upper airway obstruction or sleep apnea or severe respiratory impairment" was added. Also updating description, guidelines, regulatory status, rationale and references.
11/01/2016	Annual review, no change to policy intent. updating background, description, rationale and references.
09/16/2015	Annual review, no change to policy intent. Updated background, desrciption, rationale, references and coding.
09/18/2014	New Policy

Policy List

Edit Policy

{{ navigationConstituentPage.title || (navigationSitePage.urlName == 'medicalpolicyhb' ? 'Healthy Blue Medical Policies' : 'Medical Policies') }}

Human Growth Hormone - CAM 339

Codes

Number

Description